STOCK TITAN

Myriad Genetics director proposes sale of 6,100 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Mark Steven Davis, a director of Myriad Genetics Inc., gave notice of a proposed sale of 6,100 common shares, with an aggregate market value of $34,251.50 and an approximate sale date of November 18, 2026. The listed shares came from restricted stock vesting: 2,100 shares acquired on December 10, 2025 and 4,000 shares acquired on June 4, 2026.

Shares listed for sale 6,100 shares Approximate sale date: November 18, 2026
Aggregate market value $34,251.50 For the 6,100 common shares listed for sale
Common shares outstanding 95,922,196 shares Reported in the notice
Shares acquired through restricted stock vesting 2,100 shares Acquired on December 10, 2025
Shares acquired through restricted stock vesting 4,000 shares Acquired on June 4, 2026
Restricted Stock Vesting financial
"Acquired through restricted stock vesting"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MYGN shares did Mark Steven Davis plan to sell?

Mark Steven Davis, a director of Myriad Genetics Inc., reported a proposed sale of 6,100 common shares, with an aggregate market value of $34,251.50 and an approximate sale date of November 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading